Andrea Eleazar, MHS

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.

NCCN adds ctDNA-MRD testing after cystectomy, using Signatera to identify MIBC patients who may benefit from adjuvant atezolizumab.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

FDA reviews chemo-free mosunetuzumab plus polatuzumab for relapsed/refractory LBCL, promising outpatient second-line care and longer PFS.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

LOTIS-5 finds loncastuximab tesirine plus rituximab improves PFS and response rates in relapsed/refractory DLBCL vs R-GemOx.

FDA approves Cavhanza, a nilotinib orally disintegrating tablet for adult Ph+ CML, enabling use with PPIs/H2RAs and meals for easier dosing.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma.

The bezuclastinib/sunitinib combo is being reviewed by the FDA for approval in GIST based on the PEAK study findings.

Prior RAMPART results had shown durvalumab plus tremelimumab significantly improved DFS in resected renal cell carcinoma.

“We believe that the combination of [Tafa-Len-R-CHOP] is a potential new standard for frontline therapy for patients with intermediate or high-risk [DLBCL] or [HGBL],” said Georg Lenz, MD.

SUCCESSOR-2 shows oral mezigdomide plus carfilzomib/dexamethasone extends PFS to 18 months in high-risk relapsed myeloma.

Long-term RUBY data show dostarlimab plus chemo drives durable remission and potential cure in many patients with dMMR/MSI-H advanced or recurrent endometrial cancer.

FDA grants orphan drug status to EO2463 vaccine for watch-and-wait indolent NHL, advancing a potential treatment option and spotlighting promising SIDNEY trial data.

FLAIR finds ibrutinib‑rituximab matches FCR quality of life in untreated CLL over 4 years, with distinct adverse‑effect tradeoffs.

FDA fast tracks STX-0712, a CCR2-targeted CyTAC, as phase 1 trial enrolls to tackle relapsed/refractory CMML and monocytic AML.

New survey reveals CLL physicians and patients vary widely on post-BTK inhibitor tradeoffs, urging shared decisions beyond survival data.

FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.

Older men with CLL on BTK inhibitors face sharply higher atrial fibrillation risk, shaping drug choice and prompting stronger cardiovascular screening and monitoring.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

Decade-long trial shows continuous ibrutinib delivers durable survival in high-risk or older CLL, with emerging uMRD and manageable cardiac risks.

FDA grants orphan status to CLN‑049, an FLT3xCD3 T‑cell engager in phase 1, for relapsed/refractory patients with AML.

Rural patients with cancer face crushing costs, travel hurdles, and medical debt; new ACS CAN data show care delays and highlights patient navigation as relief.

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and patients face next.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

Final PRIMO phase 2 data show oral duvelisib drives strong responses in relapsed PTCL, standout AITL benefit, with manageable safety signals.